Kalytera Therapeutics, Inc. announced that it expects to receive CAD 12 million in funding from Anson Fund Managers Limited, Aphria Inc.

Kalytera Therapeutics, Inc. (TSXV:KALY) announced a best efforts brokered private placement private placement of 24,000,000 common shares at CAD 0.50 per share for gross proceeds of CAD 12,000,000 on January 23, 2017. The securities issued are subject to four months and one day hold period from the date of closing. The transaction is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the negotiation and execution of definitive documentation.

The transaction is expected to close on or about February 7, 2017.